Literature DB >> 24236369

Health inequities experienced by Aboriginal children with respiratory conditions and their parents.

Miriam Stewart1, Malcolm King, Roxanne Blood, Nicole Letourneau, Jeffrey R Masuda, Sharon Anderson, Lisa Bourque Bearskin.   

Abstract

Asthma and allergies are common conditions among Aboriginal children and adolescents. The purpose of this study was to assess the health and health-care inequities experienced by affected children and by their parents. Aboriginal research assistants conducted individual interviews with 46 Aboriginal children and adolescents who had asthma and/or allergies (26 First Nations, 19 Métis, 1 Inuit) and 51 parents or guardians of these children and adolescents. Followup group interviews were conducted with 16 adolescents and 25 parents/ guardians. Participants reported inadequate educational resources, environmental vulnerability, social and cultural pressures, exclusion, isolation, stigma, blame, and major support deficits. They also described barriers to health-service access, inadequate health care, disrespectful treatment and discrimination by health-care providers, and deficient health insurance. These children, adolescents, and parents recommended the establishment of culturally appropriate support and education programs delivered by Aboriginal peers and health professionals.

Entities:  

Mesh:

Year:  2013        PMID: 24236369     DOI: 10.1177/084456211304500302

Source DB:  PubMed          Journal:  Can J Nurs Res        ISSN: 0844-5621


  2 in total

Review 1.  Culture-specific programs for children and adults from minority groups who have asthma.

Authors:  Gabrielle B McCallum; Peter S Morris; Ngiare Brown; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2017-08-22

2.  Asthma Prevention and Management for Aboriginal People: Lessons From Mi'kmaq Communities, Unama'ki, Canada, 2012.

Authors:  Heather Castleden; Robert Watson; Ella Bennett; Jeffrey Masuda; Malcolm King; Miriam Stewart
Journal:  Prev Chronic Dis       Date:  2016-01-14       Impact factor: 2.830

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.